title: [Clinical and pathological features of borderline ovarian tumors].
abstract: OBJECTIVE
  To study the relationship between clinical pathological factors and prognosis.
  
  
  METHODS
  Thirty-four cases with borderline ovarian tumors (BOT) and 30 cases with stage I ovarian epithelial cancer admitted in our hospital from Jan.1973 to Dec.2000 were studied retrospectively. All the cases were diagnosed according to the International Histological Classification and Staging of Ovarian Tumors (WHO, 1999).
  
  
  RESULTS
  Thirty-seven cases were finally diagnosed of BOT, 6 cases with "microinvasive" had been misinterpreted as stage I ovarian cancer and one had "non-invasive peritoneal implants". Serous (38%) and mucinous (51%) tumors were dominant type of BOT and 95% of tumors were at stage I (International Federation of Gynecology and Obstetrics, FIGO). All patients were operated, 11 cases given conservative surgery with a recurrence rate of 9%, 26 cases had adjuvant chemotherapy, cyclophosphamide + adriamycin + cis-platinum used mostly. 5-year and 10 year survival rates were both 100%. The prognosis of BOT is related to pathology and adjuvant therapy.
  
  
  CONCLUSIONS
  Surgery is the main treatment choice of BOT, and the criteria of chemotherapy must be adequately used.
authors.affiliation: Department of Gynecologic Oncology Center, People's Hospital, Peking University, Beijing 100044, China.
authors.forename: Yi
authors.initials: Y
authors.lastname: Li
authors.forename: Heng
authors.initials: H
authors.lastname: Cui
authors.forename: Dan-hua
authors.initials: DH
authors.lastname: Shen
authors.forename: Yan
authors.initials: Y
authors.lastname: Zhao
authors.forename: Li-hui
authors.initials: LH
authors.lastname: Wei
authors.forename: He-nian
authors.initials: HN
authors.lastname: Qian
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D018282:Cystadenocarcinoma, Mucinous / Q000188:drug therapy / Q000401:mortality / Q000473:pathology*; D018284:Cystadenocarcinoma, Serous / Q000188:drug therapy / Q000401:mortality / Q000473:pathology*; D005260:Female; D006801:Humans; D008875:Middle Aged; D009361:Neoplasm Invasiveness; D009367:Neoplasm Staging; D010051:Ovarian Neoplasms / Q000188:drug therapy / Q000401:mortality / Q000473:pathology*; D011379:Prognosis; D012189:Retrospective Studies; D015996:Survival Rate